Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

OBJECTIVES:

Primary

- Identify molecular characteristics that predict for overall survival and
progression-free survival of patients treated with erlotinib hydrochloride,
temozolomide, and radiotherapy on clinical trial NCCTG-N0177.

Secondary

- Identify molecular characteristics that predict for overall survival and
progression-free survival of patients treated with gefitinib after radiotherapy on
clinical trial NCCTG-N0074.

OUTLINE: This is a multicenter study.

Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are
analyzed by microarray analysis and immunohistochemistry for biological markers predicting
progression-free survival and overall survival. Biological markers include epidermal growth
factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2,
ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

All patients entered onto N0177 and N0074 who have appropriate archived clinical specimens.